Business, energy, technology, markets and global industry news from Business News Today

Eli Lilly and Company

PharmaDeviceNews Eli Lilly and Company
Representative image: Scientists review DNA delivery and lipid nanoparticle research in a genetic medicines lab as Eli Lilly’s Engage Bio acquisition highlights the growing race to solve non-viral drug delivery challenges.
Pharma & Biotech

Eli Lilly expands genetic medicines toolkit with Engage Bio’s non-viral DNA delivery system

Eli Lilly’s Engage Bio deal is small by its standards, but DNA delivery may become a big battleground in genetic medicines.

Read More
Representative image: Advanced liver cancer imaging and RNA-based oncology research illustrate Rznomics Inc.’s FDA RMAT designation for RZ-001 in hepatocellular carcinoma, highlighting the growing role of RNA editing in next-generation cancer therapy.
Pharma & Biotech

FDA RMAT status puts Rznomics’ RNA editing platform under a brighter clinical spotlight

RNA editing just gained a liver cancer spotlight. Rznomics must now prove RZ-001 can turn early response signals into durable clinical value.

Read More
Representative image of a modern U.S. pharmaceutical manufacturing campus, highlighting how Eli Lilly’s $4.5 billion Indiana expansion could strengthen domestic drug production capacity for obesity, diabetes and advanced genetic medicines.
Pharma & Biotech

Could Eli Lilly’s $4.5bn Indiana investment widen its lead in obesity and advanced therapies?

Obesity drug demand is outrunning pharma capacity. Eli Lilly’s Indiana bet shows manufacturing is now a strategic moat.

Read More
Representative image: Novo Nordisk’s Wegovy pill launch in the U.S. obesity drug market is illustrated through unbranded tablets, prescription growth data and healthcare market signals, reflecting rising demand for oral GLP-1 weight-loss treatments.
Pharma & Biotech

Can Novo Nordisk’s Wegovy pill reshape the obesity market before Eli Lilly catches up?

Novo Nordisk has the first-mover pill. Eli Lilly has the growth aura. Oral obesity drugs are turning access into the next GLP-1 battleground.

Read More
Representative image of an oral obesity treatment concept illustrating how Eli Lilly and Company’s Foundayo approval could widen access to GLP-1 weight loss therapy and reshape the next phase of the obesity drug market.
Pharma & Biotech

Eli Lilly and Company’s Foundayo approval could widen the obesity market faster than rivals expected

Eli Lilly and Company’s Foundayo approval could reshape obesity treatment. Read what the oral GLP-1 launch changes for clinicians, payers, and rivals.

Read More
Zepbound KwikPen arrives on Ro as Eli Lilly tightens control over obesity drug distribution
Medical Devices & Diagnostics

Why the Ro and Eli Lilly KwikPen move matters for obesity drug access, adherence, and pricing

Ro launches Eli Lilly’s Zepbound KwikPen nationwide. Read what this means for GLP-1 access, pricing, adherence, and obesity care models.

Read More
Pharma & Biotech

Scribe Therapeutics deepens in vivo CRISPR validation with second Eli Lilly collaboration milestone

Scribe Therapeutics hits a second in vivo CRISPR milestone with Eli Lilly. Explore what this changes for gene editing platforms and future therapies.

Read More
Pharma & Biotech

Why Lilly’s LIBRETTO-432 results matter beyond selpercatinib’s event-free survival win

Eli Lilly and Company (Lilly) announced that its selective RET inhibitor selpercatinib, marketed as Retevmo, achieved a highly statistically significant improvement in investigator-assessed event-free survival when used as adjuvant therapy in patients with stage II–IIIA RET fusion-positive non-small cell lung cancer, based on topline results from the Phase 3 LIBRETTO-432 trial. The study compared selpercatinib

Read More
Pharma & Biotech

What Lilly’s Orna Therapeutics deal means for immune reset strategies

Eli Lilly and Company has entered into a definitive agreement to acquire Orna Therapeutics, Inc., gaining access to the biotechnology firm’s circular RNA platform and its clinical trial ready in vivo CAR-T candidate ORN-252 targeting CD19 for B cell driven autoimmune diseases. The deal, valued at up to 2.4 billion dollars in cash including milestone

Read More
Eli Lilly and Company has committed $3.5 billion toward a new Pennsylvania facility dedicated to manufacturing next-generation injectable medicines, including retatrutide.
Pharma & Biotech

Lilly’s $3.5bn Pennsylvania site will anchor U.S. manufacturing for next-gen injectables including retatrutide

Eli Lilly and Company has announced a $3.5 billion investment to build a new injectable medicine and device manufacturing facility in Lehigh Valley, Pennsylvania. The site will focus on producing next-generation weight-loss medicines, including the investigational triple hormone receptor agonist retatrutide. Set to become operational by 2031, this is Lilly’s fourth new U.S. manufacturing site

Read More